Birmingham, AL: Epilepsy patients administered the standardized CBD extract Epidiolex experience a significant reduction in seizures over an extended period of time, according to clinical trial data published in the journal Epilepsy & Behavior.
Investigators at the University of Alabama at Birmingham assessed the long-term daily administration of Epidiolex in a cohort of 132 patients with intractable epilepsy. Authors reported that subjects experienced “significant improvements” in their adverse events profile and in seizure frequency at 12 weeks and that most sustained these improvements over 48 weeks of treatment.
In June, the US Food and Drug Administration granted market approval for the prescription use of Epidiolex in the treatment of two rare forms of pediatric epilepsy: Lennox-Gastaut syndrome and Dravet’s syndrome. The retail price of the new drug is estimated to be $32,500 per year.